Led by John Buse, MD, PhD, director of the UNC Diabetes Care Center, the clinical research of UNC doctors and the participation of thousands of patients culminates in a new, effective, and safe daily injectable drug to combat type-2 diabetes.
For the first time, a large clinical trial showed across-the-board cardiovascular benefit of a diabetes drug – liraglutide – a much-needed outcome for people with type 2 diabetes.
CTSA collaborative funding award supports mouse-model research. Nigel Mackman, PhD, of UNC, and Rebekah White, MD, of Duke are leading the effort.
UNC / NC State researchers devise a new nanotechnology to enhance the body’s own immune response to kill skin cancer tumors.
The new cancer drug delivery system improved efficacy of standard chemotherapy for ovarian cancer in mice with limited toxicity.
